Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772547 · ClinicalTrials.gov registry record · Phase 2
VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04772547: Completed Phase 2 study, sponsored by University of Florida.
NCT04772547 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04772547, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a pilot trial of a single loading dose of vigabatrin in post-anoxic status epilepticus.
Primary Outcome
By analyzing serial vigabatrin levels including baseline, we characterized vigabatrin absorption; the target was to achieve a detectable vigabatrin level in the serum of ≥ 80% of enrolled subjects by 3 hours post-load.
Interventions
- DRUG Vigabatrin Only Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
What the finished NCT04772547 record still lists
NCT04772547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Vigabatrin Only Product is the first listed.
NCT04772547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04772547 about?
NCT04772547 is a clinical study titled "VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa". This is a pilot trial of a single loading dose of vigabatrin in post-anoxic status epilepticus.
What is the current status of trial NCT04772547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-09-22. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT04772547?
The interventions under investigation include: Vigabatrin Only Product (DRUG).
Who is sponsoring clinical trial NCT04772547?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04772547's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI